ASH 2024: Kite Pharma's global head discusses the progress of the CAR-T field, Arcellx's BCMA data, cures in CD19, autoimmune, and future targets

blonca9
Dec 9, 2024
1 min read

Cindy Perettie describes why she took the head job at Kite a little over a year ago, long-term CD19 data, tonight's BCMA update, Kite's approach to autommite, a glioblastoma program, and more.

Recent Posts

See All

RBC Global Healthcare Conference: Korro Bio entered the clinic with its RNA editing platform in January and will have multiple cohorts of data in AATD later this year

RBC Global Healthcare Conference: With a phase 3 for its lead program scheduled to read in Q3 and mid-stage data for another program coming up this quarter, aTyr Pharma has pivotal months ahead

RBC Global Healthcare Conference: Ocular Therapeutix's Chairman & CEO Pravin Dugel provides an update on the progress of the pivotal studies for AXPAXLI in wet AMD

ASH 2024: Kite Pharma's global head discusses the progress of the CAR-T field, Arcellx's BCMA data, cures in CD19, autoimmune, and future targets

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight